Eli Lilly is building four new manufacturing sites, the drug company announced Wednesday, and though the $27 billion price tag is hefty, that’s not the notable piece of the announcement. Perhaps the more interesting part is that the sites are being located in the U.

Eli Lilly and Co. plans to bolster its domestic medicine production with a $27B investment in four new U.S. pharmaceutical manufacturing sites, bringing its total capital commitment to future expansion to more than $50B.

Eli Lilly plans to spend $27 billion to build new drug manufacturing sites in the U.S., at a time when President Trump is seeking to press drugmakers to move stateside.